Dr. Lal PathLabs (LALPATHLAB) Stock Overview
Operates laboratories for carrying out pathological investigations in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
LALPATHLAB Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Dr. Lal PathLabs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,953.30 |
| 52 Week High | ₹1,988.90 |
| 52 Week Low | ₹1,272.60 |
| Beta | 0.19 |
| 1 Month Change | 13.23% |
| 3 Month Change | 22.07% |
| 1 Year Change | 18.55% |
| 3 Year Change | 71.18% |
| 5 Year Change | -2.44% |
| Change since IPO | 373.53% |
Recent News & Updates
Narrative Update • Aug 08
LALPATHLAB: Rich Multiple And Softer Margins Will Pressure Future Returns
The analyst price target for Dr. Lal PathLabs has been revised higher from ₹1,313.62 to ₹1,453.15, with analysts pointing to updated fair value assumptions and a slightly different blend of discount rate, revenue growth, profit margin and future P/E inputs to support the change. What's in the News for Dr. Lal PathLabs Dr. Lal PathLabs scheduled a Board meeting on July 24, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.Analysis Article • Jul 28
Dr. Lal PathLabs Limited Just Missed Earnings - But Analysts Have Updated Their Models
Investors in Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) had a good week, as its shares rose 7.9% to close at ₹1,827...Recent updates
Narrative Update • Aug 08
LALPATHLAB: Rich Multiple And Softer Margins Will Pressure Future Returns
The analyst price target for Dr. Lal PathLabs has been revised higher from ₹1,313.62 to ₹1,453.15, with analysts pointing to updated fair value assumptions and a slightly different blend of discount rate, revenue growth, profit margin and future P/E inputs to support the change. What's in the News for Dr. Lal PathLabs Dr. Lal PathLabs scheduled a Board meeting on July 24, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026.Analysis Article • Jul 28
Dr. Lal PathLabs Limited Just Missed Earnings - But Analysts Have Updated Their Models
Investors in Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) had a good week, as its shares rose 7.9% to close at ₹1,827...
Narrative Update • Jul 25
LALPATHLAB: Dividends And Dubai Expansion Will Support Long Term Upside
Analysts have nudged their fair value estimate for Dr. Lal PathLabs up from about ₹1,664 to roughly ₹1,745, reflecting updated assumptions on revenue growth, profit margins and future P/E multiples. What's in the News Dr. Lal PathLabs approved an interim dividend of ₹5 per equity share on a face value of ₹10 each for FY 2026-27, with a record date of July 30, 2026 and payout within 30 days of declaration.
Narrative Update • Jun 23
LALPATHLAB: Dividend And Dubai Expansion Will Support Future Upside
Analysts have kept their fair value estimate for Dr. Lal PathLabs steady at about ₹2,058 per share, while modestly updating their underlying assumptions on revenue growth, profit margins, and future P/E to reflect a slightly refined outlook on the company's earnings power. What's in the News A board meeting is scheduled for April 30, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend on equity shares for FY 2025-26.Narrative Update • Jun 05
LALPATHLAB: Dubai Expansion Will Test Premium Pricing And Pressure Future Returns
Analysts have raised their fair value estimate for Dr. Lal PathLabs from about ₹1,266 to roughly ₹1,314, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News The Board has recommended a final dividend of ₹4 per equity share, at 40% on a face value of ₹10, for the financial year ended March 31, 2026, subject to approval by shareholders at the upcoming Annual General Meeting.Narrative Update • May 22
LALPATHLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish View
Analysts have trimmed their price target on Dr. Lal PathLabs from ₹2,375.80 to ₹2,058.38 as they factor in revised assumptions around revenue growth, profit margins and future P/E expectations. What's in the News A board meeting is scheduled for April 30, 2026, to review and approve audited standalone and consolidated financial results for the quarter and full year ending March 31, 2026 (company filing).Narrative Update • May 04
LALPATHLAB: Upcoming Results And Dividend Decision Will Support Bullish View
Analysts have made a marginal upward adjustment to the fair value estimate for Dr. Lal PathLabs, nudging the target to about ₹2,375.80 as they factor in updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News The board meeting is scheduled for April 30, 2026 to review and approve the audited standalone and consolidated financial results for the quarter and full year ending March 31, 2026 (company filing).Analysis Article • May 03
Here's What Analysts Are Forecasting For Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Yearly Results
Shareholders might have noticed that Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) filed its full-year result this time...Narrative Update • Apr 20
LALPATHLAB: Upcoming Audited Results Will Support Revised Bullish Outlook
Analysts have adjusted their price target on Dr. Lal PathLabs from about ₹2,084 to roughly ₹2,375, citing revised assumptions around revenue growth, profit margin and future P/E expectations. What's in the News A board meeting is scheduled for April 30, 2026, to consider and approve the audited standalone financial results for the quarter and financial year ending March 31, 2026 (company filing).Narrative Update • Apr 06
LALPATHLAB: Cardiac Testing Collaboration And New Wellness Centre Will Support Future Earnings
Analysts have nudged their fair value estimate for Dr. Lal PathLabs higher from about ₹2,067.53 to roughly ₹2,083.69, reflecting updated assumptions around revenue growth, profit margins, and future P/E levels. What's in the News Upcoming board meeting on Apr 30, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and financial year ending Mar 31, 2026 (company filing).Narrative Update • Mar 23
LALPATHLAB: New Cardiac And Wellness Offerings Will Shape Steady Forward Outlook
Analysts have slightly reduced their fair value estimate for Dr. Lal PathLabs to about ₹1,266 from roughly ₹1,286, reflecting updated expectations for revenue growth, profit margins and future P/E assumptions. What's in the News Dr. Lal PathLabs, Cardio Diagnostics Holdings and Aimil have agreed to launch the PrecisionCHD test in India, bringing a clinically validated blood test for coronary heart disease that uses genetics, epigenetics and AI to the company's network.Narrative Update • Mar 08
LALPATHLAB: Specialty Heart Testing Partnership Will Support Future Earnings Strength
Analysts have slightly trimmed their fair value estimate for Dr. Lal PathLabs from ₹2,080 to about ₹2,068, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Cardio Diagnostics Holdings, Aimil and Dr. Lal PathLabs agreed to launch the PrecisionCHD blood test in India for detection and management of coronary heart disease.Narrative Update • Feb 22
LALPATHLAB: Future Diagnostics Expansion And Capital Structure Changes Will Shape Balanced Outlook
Analysts have revised their price target on Dr. Lal PathLabs to ₹1,286 from ₹2,368, reflecting updated assumptions around slightly lower revenue growth, a modestly higher future P/E of 42.7x, and a broadly stable profit margin profile. What's in the News Cardio Diagnostics Holdings, Aimil and Dr. Lal PathLabs have entered into an agreement to introduce the PrecisionCHD blood test for coronary heart disease in India, with initial integration into Dr. Lal PathLabs' network underway and a broader commercial rollout targeted for 2026 (Key Developments).Narrative Update • Feb 08
LALPATHLAB: New Diagnostic Platforms Will Support Long Term Upside
Analysts have cut their price target on Dr. Lal PathLabs from ₹3,428.15 to ₹1,663.88, citing updated assumptions around slightly higher revenue growth, a modestly lower profit margin, a reduced discount rate of 12.48%, and a revised future P/E estimate of 52.58x. What's in the News Cardio Diagnostics Holdings, Aimil and Dr. Lal PathLabs agreed to launch the PrecisionCHD blood test for coronary heart disease detection and management in India.Analysis Article • Feb 03
Dr. Lal PathLabs Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Investors in Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) had a good week, as its shares rose 3.0% to close at ₹1,418...Narrative Update • Jan 25
LALPATHLAB: Specialty Testing And Wellness Expansion Will Support Future Earnings Strength
Analysts have adjusted their price target for Dr. Lal PathLabs from ₹2,000 to ₹2,080, reflecting updated assumptions around profit margins and future P/E expectations. What's in the News Cardio Diagnostics, Aimil and Dr. Lal PathLabs agreed to launch the PrecisionCHD blood test for coronary heart disease detection and management in India, marking Cardio Diagnostics' first move outside the US and an expansion of advanced CHD diagnostics using epigenetics, genetics and AI (Key Developments).Narrative Update • Jan 11
LALPATHLAB: Expanded Specialty Testing Network Will Support Long-Term Earnings Strength
Analysts have maintained their fair value estimate for Dr. Lal PathLabs at ₹2,000.00 per share, citing only slight adjustments in revenue growth, profit margin and future P/E assumptions as the main reasons for keeping the target unchanged. What's in the News Cardio Diagnostics, Aimil and Dr. Lal PathLabs agreed to launch the PrecisionCHD blood test for coronary heart disease in India, marking Cardio Diagnostics' first move outside the US and an effort to align the test with Indian clinical and regulatory protocols before a planned commercial rollout in 2026 (Strategic Alliances).Analysis Article • Jan 02
Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Might Deserve Your Attention Today
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative Update • Dec 23
LALPATHLAB: Expanded Autoimmune Diagnostics Will Drive Long-Term Earnings Strength
Analysts have reduced their price target for Dr. Lal PathLabs from ₹4,020 to ₹2,000 per share, citing a modest uptick in long term revenue growth assumptions along with slightly lower projected profit margins and valuation multiples. What's in the News Shareholders approved an alteration to the capital clause of the Memorandum of Association, increasing authorized share capital to INR 2,00,00,00,000.Analysis Article • Dec 12
Dr. Lal PathLabs (NSE:LALPATHLAB) Could Become A Multi-Bagger
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Narrative Update • Dec 09
LALPATHLAB: New Autoimmune Lab And Dividend Will Support Long Term Upside
Analysts have nudged their price target for Dr. Lal PathLabs slightly higher to ₹3,428 from ₹3,421, citing marginally stronger expectations for long term revenue growth and profit margins, along with a modestly lower future P E multiple. What's in the News Launch of India's first dedicated Complement Testing Laboratory, positioning Dr. Lal PathLabs as a leading national hub for advanced autoimmune diagnostics and complement assays (company announcement).Narrative Update • Nov 25
LALPATHLAB: Shareholder Approvals And Margin Trends Will Influence Outlook
Analysts have raised their price target for Dr. Lal PathLabs from ₹3,360.44 to ₹3,420.80. This adjustment reflects incremental improvements in revenue growth expectations despite a slight dip in projected profit margins.Narrative Update • Nov 10
LALPATHLAB: Future Margins And Early Cancer Detection Will Shape Outlook
Analysts have raised their price target for Dr. Lal PathLabs from ₹3,284.28 to ₹3,360.44, citing improved profit margins, even though revenue growth projections are slightly softer. What's in the News Dr. Lal PathLabs adopted a deep learning-based AI module to detect lymph node metastasis in cancer cases, achieving 100% sensitivity and enabling earlier and more accurate diagnoses (Product-Related Announcements).Analysis Article • Nov 07
Dr. Lal PathLabs (NSE:LALPATHLAB) Is Increasing Its Dividend To ₹7.00
Dr. Lal PathLabs Limited's ( NSE:LALPATHLAB ) periodic dividend will be increasing on the 30th of November to ₹7.00...Analysis Article • Sep 29
Here's Why We Think Dr. Lal PathLabs (NSE:LALPATHLAB) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Sep 01
Under The Bonnet, Dr. Lal PathLabs' (NSE:LALPATHLAB) Returns Look Impressive
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Aug 18
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
NSEI:LALPATHLAB 1 Year Share Price vs Fair Value Explore Dr. Lal PathLabs's Fair Values from the Community and select...Analysis Article • Aug 05
Dr. Lal PathLabs Limited Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next
It's been a good week for Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) shareholders, because the company has just...Analysis Article • Jul 25
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Shares May Have Run Too Fast Too Soon
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 29x, you may consider Dr...Analysis Article • Jun 24
Is Now The Time To Put Dr. Lal PathLabs (NSE:LALPATHLAB) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysis Article • Jun 03
Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00
Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) has announced that it will pay a dividend of ₹6.00 per share on the 28th of...Analysis Article • Apr 28
Dr. Lal PathLabs (NSE:LALPATHLAB) Has Affirmed Its Dividend Of ₹6.00
The board of Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) has announced that it will pay a dividend on the 28th of July...Analysis Article • Apr 25
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Business Is Trailing The Market But Its Shares Aren't
With a price-to-earnings (or "P/E") ratio of 55.7x Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) may be sending very...Analysis Article • Mar 04
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...
New Narrative • Feb 18
Expansion Into Tier 2 And Tier 3 Towns Will Enhance Access To Diagnostic Services In India
Government health spending and rising NCD prevalence are likely to boost Dr. Lal PathLabs' patient volumes and revenues.Analysis Article • Feb 03
Analyst Estimates: Here's What Brokers Think Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) After Its Third-Quarter Report
Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) last week reported its latest third-quarter results, which makes it a good...Analysis Article • Jan 16
Investor Optimism Abounds Dr. Lal PathLabs Limited (NSE:LALPATHLAB) But Growth Is Lacking
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 30x, you may consider Dr...Analysis Article • Jan 01
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Oct 26
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results
Dr. Lal PathLabs Limited ( NSE:LALPATHLAB ) shareholders are probably feeling a little disappointed, since its shares...Analysis Article • Oct 24
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Analysis Article • Oct 06
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 33x, you may consider Dr...Analysis Article • Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve
Dr. Lal PathLabs Limited's ( NSE:LALPATHLAB ) strong earnings report was rewarded with a positive stock price move. We...Shareholder Returns
| LALPATHLAB | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | 3.5% | -0.4% | 0.3% |
| 1Y | 18.5% | 6.3% | 5.2% |
Return vs Industry: LALPATHLAB exceeded the Indian Healthcare industry which returned 6.3% over the past year.
Return vs Market: LALPATHLAB exceeded the Indian Market which returned 5.2% over the past year.
Price Volatility
| LALPATHLAB volatility | |
|---|---|
| LALPATHLAB Average Weekly Movement | 3.6% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
Stable Share Price: LALPATHLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: LALPATHLAB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,206 | Shankha Banerjee | www.lalpathlabs.com |
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs.
Dr. Lal PathLabs Limited Fundamentals Summary
| LALPATHLAB fundamental statistics | |
|---|---|
| Market cap | ₹326.32b |
| Earnings (TTM) | ₹5.42b |
| Revenue (TTM) | ₹28.91b |
60.2x
P/E Ratio11.3x
P/S RatioIs LALPATHLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LALPATHLAB income statement (TTM) | |
|---|---|
| Revenue | ₹28.91b |
| Cost of Revenue | ₹11.50b |
| Gross Profit | ₹17.40b |
| Other Expenses | ₹11.99b |
| Earnings | ₹5.42b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 32.44 |
| Gross Margin | 60.20% |
| Net Profit Margin | 18.74% |
| Debt/Equity Ratio | 7.8% |
How did LALPATHLAB perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield49%
Payout RatioDoes LALPATHLAB pay a reliable dividends?
See LALPATHLAB dividend history and benchmarks| Dr. Lal PathLabs dividend dates | |
|---|---|
| Ex Dividend Date | Jun 25 2026 |
| Dividend Pay Date | Aug 23 2026 |
| Days until Ex dividend | 49 days |
| Days until Dividend pay date | 10 days |
Does LALPATHLAB pay a reliable dividends?
See LALPATHLAB dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/12 17:16 |
| End of Day Share Price | 2026/08/12 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dr. Lal PathLabs Limited is covered by 51 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hrishikesh Patole | 360 ONE Capital Market Private Limited |
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| null null | 360 ONE Capital Market Private Limited |